The European Medicines Agency (EMA) has published a document detailing the scientific advice and protocol assistance adopted during the Committee for Medicinal Products for Human Use (CHMP) meeting held from 20 to 23 April 2026. The document lists the recommendations provided to pharmaceutical companies on development plans for new medicines, including guidance on clinical trial design, quality requirements, and regulatory strategies. This publication is part of EMA's transparency efforts, offering stakeholders insight into the agency's scientific opinions and helping to harmonise drug development approaches across the EU.
The document, released on 21 May 2026, covers advice given during the April CHMP meeting. It includes summaries of the scientific questions addressed and the committee's recommendations, though it does not disclose confidential commercial information. The advice is non-binding but serves as a key reference for companies seeking regulatory alignment before submitting marketing authorisation applications. The publication also notes that some advice was adopted by written procedure outside the meeting.
Policy orientations and trade-offs
The scientific advice process balances the need for rigorous evidence to ensure patient safety and efficacy against the desire to accelerate access to innovative therapies. EMA's recommendations often push for more robust clinical data, which can delay development but reduce the risk of later rejection or post-market safety issues. Conversely, the agency may accept surrogate endpoints or adaptive trial designs in areas of high unmet medical need, trading certainty for speed. The document reflects these tensions, with some advice emphasising standard requirements and others allowing flexibility.
Impact on stakeholders
Pharmaceutical companies are the primary audience, as the advice directly shapes their development programmes. Clear guidance can reduce costly trial failures and regulatory delays, but following EMA's recommendations may require additional investment in larger or longer studies. National competent authorities benefit from harmonised expectations, facilitating mutual recognition of marketing authorisations. Patients may ultimately gain from more efficient development pathways, though the advice does not directly affect access or pricing. Healthcare professionals and payers are indirectly impacted, as the advice influences which evidence is available for health technology assessments.
Expected institutional follow-up
EMA will continue to publish scientific advice documents after each CHMP meeting, maintaining transparency while protecting commercial confidentiality. The advice itself may inform future EMA guidelines or reflection papers, and companies are expected to reference it in their regulatory submissions. No immediate legislative or regulatory changes are anticipated from this publication alone.
← Atlas › News › Health & Lifestyle